Dr. Reddy's Laboratories Limited ( NYSE: RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez ...

On 6th April 1999, two companies with similar science-based cultures and a shared ... value through global power and reach in sales and marketing, greater financial strategic flexibility and ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

In his new role, Petrelli will be responsible for leading the commercial organization for Gilead Canada, with a focus on ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. Chris Schott has given his Buy rating due to a ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago.

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made ...